Latest news

Stay updated with our latest insights and breakthroughs

Greywolf Therapeutics closes oversubscribed $50m Series B financing expansion, led by ICG Life Sciences Team, to accelerate and expand first-of-its-kind antigen modulation technology

Could antigen modulation address autoimmune diseases?

Greywolf appoints Darlene Deptula-Hicks as Chief Financial Officer

Greywolf Therapeutics to Present First Clinical Data for GRWD5769, a First-in-Class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting

Promising preclinical data reported at AACR 2023

Announcing the dosing of first patient in our clinical study

$49 Million Series B financing oversubscribed

Supply agreement with Regeneron for GRWD5769 clinical trial

Brett Carter joins board of Directors of Australian subsidiary

Formation of our Clinical Advisory Board

Preclinical data on first-in-class ERAP1 inhibitors presented at SITC

£1.1m InnovateUK grant funding to accelerate ERAP1 inhibitor programme

£2.5m Series A2 financing for development of therapies targeting ERAP2

GWT completes £10m ($14m) series A financing

Discover how our therapies are reshaping treatment for various diseases and conditions.

Harnessing antigen modulation to empower T cells against diseases.